On August 7, 2024, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab). This approval, designated as a supplemental efficacy application, was sponsored by Merck Sharp Dohme.
Background
A supplemental application, such as the one approved for Keytruda (pembrolizumab), is submitted to the FDA to request changes to a drug's existing approval. These changes can include new indications, new dosing regimens, new routes of administration, or manufacturing changes. In this instance, the supplemental application was specifically for efficacy, indicating that new clinical data supported an expansion or modification of the drug's approved uses based on its effectiveness. Pembrolizumab is developed by Merck Sharp Dohme.
What this means
The FDA's supplemental approval for Keytruda (pembrolizumab) on August 7, 2024, signifies a regulatory endorsement of its efficacy for an expanded or new indication. Supplemental applications for efficacy are typically submitted when new clinical data supports the use of an approved drug in a different patient population, for an additional disease, or under modified conditions of use. This type of approval allows Merck Sharp Dohme to update the drug's label, providing clinicians with updated guidance on its appropriate application. For patients, this could mean access to pembrolizumab for previously unapproved conditions or populations, potentially broadening therapeutic options.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-157 was posted on August 7, 2024, on accessdata.fda.gov.